Gilead Sciences Inc. (GILD) Rating Reiterated by Goldman Sachs Group Inc.
Gilead Sciences Inc. (NASDAQ:GILD)‘s stock had its “neutral” rating reaffirmed by research analysts at Goldman Sachs Group Inc. in a note issued to investors on Tuesday. They presently have a $80.00 price target on the biopharmaceutical company’s stock. Goldman Sachs Group Inc.’s price objective indicates a potential upside of 1.30% from the company’s previous close.
Several other equities analysts have also weighed in on the stock. Piper Jaffray Cos. reiterated a “buy” rating and issued a $108.00 target price on shares of Gilead Sciences in a report on Monday, August 15th. Jefferies Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the company from $76.89 to $91.00 in a report on Tuesday, September 6th. Morgan Stanley reiterated a “hold” rating and issued a $103.00 target price on shares of Gilead Sciences in a report on Wednesday, June 15th. Berenberg Bank started coverage on shares of Gilead Sciences in a report on Thursday, September 22nd. They issued a “buy” rating on the stock. Finally, Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a report on Sunday, July 10th. Eleven investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $104.34.
Shares of Gilead Sciences (NASDAQ:GILD) opened at 78.97 on Tuesday. The stock has a market capitalization of $104.21 billion, a price-to-earnings ratio of 6.93 and a beta of 1.06. The company has a 50-day moving average of $79.44 and a 200-day moving average of $85.67. Gilead Sciences has a 52-week low of $76.67 and a 52-week high of $111.11.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, topping analysts’ consensus estimates of $3.02 by $0.06. The firm had revenue of $7.78 billion for the quarter, compared to analyst estimates of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. Gilead Sciences’s quarterly revenue was down 5.7% on a year-over-year basis. During the same period in the previous year, the business posted $3.15 earnings per share. Equities research analysts anticipate that Gilead Sciences will post $11.76 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Shareholders of record on Friday, September 16th will be issued a dividend of $0.47 per share. The ex-dividend date is Wednesday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.38%. Gilead Sciences’s dividend payout ratio (DPR) is currently 16.56%.
In other Gilead Sciences news, Chairman John C. Martin sold 100,000 shares of the firm’s stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $84.73, for a total transaction of $8,473,000.00. Following the sale, the chairman now directly owns 4,119,727 shares of the company’s stock, valued at approximately $349,064,468.71. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John F. Milligan sold 112,000 shares of the firm’s stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $84.33, for a total transaction of $9,444,960.00. Following the sale, the chief executive officer now directly owns 1,170,963 shares in the company, valued at $98,747,309.79. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. Bank of Montreal Can bought a new stake in Gilead Sciences during the second quarter valued at about $427,750,000. Capital World Investors boosted its stake in Gilead Sciences by 28.3% in the second quarter. Capital World Investors now owns 15,318,948 shares of the biopharmaceutical company’s stock valued at $1,277,907,000 after buying an additional 3,380,000 shares in the last quarter. Investec Asset Management LTD bought a new stake in Gilead Sciences during the first quarter valued at about $280,342,000. Parnassus Investments CA boosted its stake in Gilead Sciences by 45.4% in the second quarter. Parnassus Investments CA now owns 8,460,484 shares of the biopharmaceutical company’s stock valued at $705,774,000 after buying an additional 2,640,284 shares in the last quarter. Finally, NN Investment Partners Holdings N.V. bought a new stake in Gilead Sciences during the first quarter valued at about $180,268,000. 77.94% of the stock is currently owned by institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.